Long non-coding RNA DSCAS regulates cisplatin sensitivity in lung squamous cell carcinoma by competitively binding to miR-646-3p

[1]  B. Bonavida,et al.  Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability. , 2022, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[2]  Joe Y. Chang,et al.  Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  Wanqing Chen,et al.  Cancer statistics in China and United States, 2022: profiles, trends, and determinants , 2022, Chinese medical journal.

[4]  A. Tan,et al.  Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[6]  Jiang Liu,et al.  FDA Approval Summary: Sotorasib for KRAS G12C Mutated Metastatic NSCLC. , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  Lihua Liu,et al.  Long non-coding RNA NORAD/miR-224-3p/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of β-catenin , 2021, Molecular cancer.

[8]  E. Brzeziańska-Lasota,et al.  Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy , 2021, International journal of molecular sciences.

[9]  K. O'Byrne,et al.  Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin , 2021, Translational oncology.

[10]  B. Sun,et al.  Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression. , 2020, European review for medical and pharmacological sciences.

[11]  M. Garofalo,et al.  Mechanisms of drug resistance mediated by long non-coding RNAs in non-small-cell lung cancer , 2020, Cancer Gene Therapy.

[12]  Jun Li,et al.  LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression , 2020, Molecular Cancer.

[13]  Dai-Ling Chao,et al.  Circular RNA has_circ_0000527 participates in proliferation, invasion and migration of retinoblastoma cells via miR‐646/BCL‐2 axis , 2020, Cell biochemistry and function.

[14]  Yang-Hsiang Lin.  Crosstalk of lncRNA and Cellular Metabolism and Their Regulatory Mechanism in Cancer , 2020, International journal of molecular sciences.

[15]  Xihua Lu,et al.  Propofol facilitates cisplatin sensitivity via lncRNA MALAT1/miR-30e/ATG5 axis through suppressing autophagy in gastric cancer. , 2020, Life sciences.

[16]  Qing Zhang,et al.  Silence of  lncRNA UCA1 rescues drug resistance of cisplatin to non–small‐cell lung cancer cells , 2019, Journal of cellular biochemistry.

[17]  A. Nicholson,et al.  The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications. , 2018, Quantitative imaging in medicine and surgery.

[18]  F. Guo,et al.  The action mechanism of lncRNA-HOTAIR on the drug resistance of non-small cell lung cancer by regulating Wnt signaling pathway , 2018, Experimental and therapeutic medicine.

[19]  M. Ladanyi,et al.  RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non–Small Cell Lung Carcinomas Sensitive to MEK Inhibition , 2017, Clinical Cancer Research.

[20]  T. Bivona,et al.  Understanding and targeting resistance mechanisms in NSCLC , 2017, Nature Reviews Cancer.

[21]  L. Wiesmüller,et al.  Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer? , 2016, Cancer treatment reviews.

[22]  L. Crinò,et al.  Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy , 2016, Medical Oncology.

[23]  Panayiotis Tsanakas,et al.  DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts , 2015, Nucleic Acids Res..

[24]  J. Chen,et al.  MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer , 2015, Cellular Physiology and Biochemistry.

[25]  J. Austin,et al.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  Zhipei Zhang,et al.  High ABCG4 Expression Is Associated with Poor Prognosis in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin-Based Chemotherapy , 2015, PloS one.

[27]  K. Syrigos,et al.  Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. , 2015, The Lancet. Oncology.

[28]  J. Gribnau,et al.  Cis- and trans-regulation in X inactivation , 2015, Chromosoma.

[29]  F. André,et al.  Targeting FGFR Signaling in Cancer , 2015, Clinical Cancer Research.

[30]  S. Dhanasekaran,et al.  The landscape of long noncoding RNAs in the human transcriptome , 2015, Nature Genetics.

[31]  Makoto Nishio,et al.  The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. , 2014, Cancer discovery.

[32]  J. Steitz,et al.  The Noncoding RNA Revolution—Trashing Old Rules to Forge New Ones , 2014, Cell.

[33]  Franck Molina,et al.  Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA , 2014, Nature Medicine.

[34]  E. Lander,et al.  The Xist lncRNA Exploits Three-Dimensional Genome Architecture to Spread Across the X Chromosome , 2013, Science.

[35]  M. Czyz,et al.  Anti-apoptotic proteins on guard of melanoma cell survival. , 2013, Cancer letters.

[36]  B. Milleron,et al.  Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Michael M Gottesman,et al.  Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes , 2012, Pharmacological Reviews.

[38]  J. Rinn,et al.  Modular regulatory principles of large non-coding RNAs , 2012, Nature.

[39]  P. Pandolfi,et al.  A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language? , 2011, Cell.

[40]  R. Houghten,et al.  A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC , 2009, British Journal of Cancer.

[41]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[42]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[43]  A. Gazdar,et al.  Apoptosis and lung cancer: A review , 2003, Journal of cellular biochemistry.

[44]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[45]  H. Lipkin.  Where is the ?c? , 1978 .

[46]  M. Shekhar,et al.  Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance. , 2015, Mutation research. Reviews in mutation research.